Advertisement
U.S. markets close in 1 hour 27 minutes
  • S&P 500

    5,253.63
    +5.14 (+0.10%)
     
  • Dow 30

    39,778.68
    +18.60 (+0.05%)
     
  • Nasdaq

    16,384.07
    -15.46 (-0.09%)
     
  • Russell 2000

    2,124.30
    +9.95 (+0.47%)
     
  • Crude Oil

    83.15
    +1.80 (+2.21%)
     
  • Gold

    2,242.40
    +29.70 (+1.34%)
     
  • Silver

    24.99
    +0.23 (+0.94%)
     
  • EUR/USD

    1.0794
    -0.0035 (-0.32%)
     
  • 10-Yr Bond

    4.2020
    +0.0060 (+0.14%)
     
  • GBP/USD

    1.2621
    -0.0017 (-0.14%)
     
  • USD/JPY

    151.3990
    +0.1530 (+0.10%)
     
  • Bitcoin USD

    70,880.55
    +2,344.88 (+3.42%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Abbott (ABT) Gains But Lags Market: What You Should Know

Abbott (ABT) closed at $98.55 in the latest trading session, marking a +0.37% move from the prior day. This change lagged the S&P 500's 1.68% gain on the day. Meanwhile, the Dow gained 1.06%, and the Nasdaq, a tech-heavy index, lost 1.7%.

Coming into today, shares of the maker of infant formula, medical devices and drugs had lost 9.52% in the past month. In that same time, the Medical sector lost 5.62%, while the S&P 500 lost 6.68%.

Abbott will be looking to display strength as it nears its next earnings release. On that day, Abbott is projected to report earnings of $0.98 per share, which would represent a year-over-year decline of 43.35%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.64 billion, down 18.98% from the year-ago period.

ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.74 billion. These results would represent year-over-year changes of -17.98% and -8.97%, respectively.

Any recent changes to analyst estimates for Abbott should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Abbott currently has a Zacks Rank of #3 (Hold).

Investors should also note Abbott's current valuation metrics, including its Forward P/E ratio of 22.41. This represents a premium compared to its industry's average Forward P/E of 21.74.

Also, we should mention that ABT has a PEG ratio of 4.4. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.24 at yesterday's closing price.

The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 149, which puts it in the bottom 41% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow ABT in the coming trading sessions, be sure to utilize Zacks.com.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Abbott Laboratories (ABT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement